Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Zentalis Pharmaceuticals ( (ZNTL) ) is now available.
On August 26, 2025, Zentalis Pharmaceuticals announced the resignation of Andrea Paul as Chief Legal Officer and Corporate Secretary, effective September 18, 2025, as she transitions to a partnership at a large international law firm. James B. Bucher, a seasoned life sciences legal executive with extensive public company experience, has been appointed as her successor. This leadership transition is expected to support Zentalis’ ongoing clinical development and potential product launch efforts, particularly for azenosertib, as the company aims to advance its registration-intent clinical trials and build shareholder value.
The most recent analyst rating on (ZNTL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Zentalis Pharmaceuticals stock, see the ZNTL Stock Forecast page.
Spark’s Take on ZNTL Stock
According to Spark, TipRanks’ AI Analyst, ZNTL is a Neutral.
Zentalis Pharmaceuticals faces significant financial hurdles, with consistent losses and negative cash flows. Technical indicators also show weak momentum. However, recent positive clinical developments provide a glimmer of hope for future growth. Despite the financial and technical challenges, the potential of azenosertib in treating aggressive cancers could offer strategic value, albeit with high risk.
To see Spark’s full report on ZNTL stock, click here.
More about Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing azenosertib, a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer. The company is evaluating azenosertib as a monotherapy and in combination across multiple tumor types in clinical trials, leveraging its extensive experience to explore additional opportunities for the drug.
Average Trading Volume: 1,000,145
Technical Sentiment Signal: Sell
Current Market Cap: $131.3M
For an in-depth examination of ZNTL stock, go to TipRanks’ Overview page.